Biocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%

MT Newswires Live01-13

Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, according to a Monday Hong Kong bourse filing.

Shares of the pharmaceutical firm were up over 9% in Tuesday morning trade.

Under the agreement, Acepodia has an option to obtain exclusive worldwide licences for two bispecific antibody-drug conjugate programs.

Biocytogen said it is eligible to receive an upfront option fee, as well as option exercise fees, development, regulatory, and commercial milestone payments, and royalties on future product sales if the options are exercised.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603571932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603571932","market":"fut","top_or_hot":-1,"title":"Biocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%","media":"MT Newswires Live","content":"<html><body><p> Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, according to a Monday Hong Kong bourse filing.</p><p>Shares of the pharmaceutical firm were up over 9% in Tuesday morning trade.</p><p>Under the agreement, Acepodia has an option to obtain exclusive worldwide licences for two bispecific antibody-drug conjugate programs.</p><p>Biocytogen said it is eligible to receive an upfront option fee, as well as option exercise fees, development, regulatory, and commercial milestone payments, and royalties on future product sales if the options are exercised.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Pharma Expands ADC Collaboration with Acepodia; Shares Rise 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-13 11:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, according to a Monday Hong Kong bourse filing.</p><p>Shares of the pharmaceutical firm were up over 9% in Tuesday morning trade.</p><p>Under the agreement, Acepodia has an option to obtain exclusive worldwide licences for two bispecific antibody-drug conjugate programs.</p><p>Biocytogen said it is eligible to receive an upfront option fee, as well as option exercise fees, development, regulatory, and commercial milestone payments, and royalties on future product sales if the options are exercised.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603571932","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603571932","pubTimestamp":1768276311,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02315":"百奥赛图-B","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ADC":"艾格里房产"},"translate_title":"百奥赛图制药扩大与Acepodia的ADC合作；股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1,"ADC":1.5},"content_text":"Biocytogen Pharmaceuticals (HKG:2315) said it has entered into an option and license agreement with Acepodia to expand its collaboration on dual-payload bispecific antibody-drug conjugate programs, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical firm were up over 9% in Tuesday morning trade.Under the agreement, Acepodia has an option to obtain exclusive worldwide licences for two bispecific antibody-drug conjugate programs.Biocytogen said it is eligible to receive an upfront option fee, as well as option exercise fees, development, regulatory, and commercial milestone payments, and royalties on future product sales if the options are exercised.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603571932","isCrawlerRequest":true}